Toggle Dropdown
Announcements
Projects
Welcome guest
Log in
Loading
Loading...
https://retractionwatch.com/2022/10/07/paper-by-gene-therapy-zolgensma-developer-retracted-because-of-discrepancies-in-mouse-survival-rates/
0
0
Paper by gene therapy Zolgensma developer retracted because of discrepancies in mouse survival rates - Retraction Watch
10/7/22 at 10:02pm
Organization
Retractionwatch.com
Authors
Details
47 words
Summarize
Science
Health Conditions
Zolgensma
mouse survival rates
Bryan Kaspar A
data inaccuracies
Bryan Kaspar A paper describing preclinical work on what appears to be the gene therapy for spinal muscular atrophy now sold as Zolgensma has been retracted for data inaccuracies. The article…
Show more
Create an account
or
login
to join the discussion
Modal title
...
Profile
Loading profile
Loading...